Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | Arthritis Research & Therapy

Figure 1

From: Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus

Figure 1

Relative expression of type I interferon-inducible mRNAs in the whole blood of rheumatic disease patients. Representative heatmap visualizing the relative expression of 807 type I interferon-inducible mRNAs in whole blood from 106 systemic lupus erythematosus (SLE) subjects (red), 20 polymyositis (PM) subjects (green), 22 dermatomyositis (DM) subjects (blue), and 66 rheumatoid arthritis (RA) subjects (pink) compared with whole blood from 24 healthy subjects (black). Fold change values are graphed for each subject and are grouped by disease.

Back to article page